House Committees Want BARDA Coronavirus Vaccine, Treatment Contract Info
Request for documents and a briefing is part of efforts to ensure federal programs are ‘protected from price gouging.’
You may also be interested in...
NCI Is Being 'Flexible' With COVID-19 Clinical Trial Protocols
At ASCO symposium on cancer care during the pandemic, NCI Director Ned Sharpless notes trial accrual at NCI's National Clinical Trials Network dropped by half in March and April.
Coronavirus Notebook: BARDA Contracting Scrutiny; Part D Cost Sharing
Dispatches from a world turned upside down covering a possible US government investigation into BARDA contracting practices and Medicare Part D plans waiving cost sharing for COVID-19 treatments.
Gilead’s Second Chance To Re-Set The Drug Price Debate
In 2014, Gilead’s launch of the “$1,000-a-pill” cure for hepatitis C triggered unprecedented political pressure around innovator drug pricing in the US. Now the company has the first effective therapy for COVID-19 – and a chance to re-set the political landscape for drug pricing once again.